Year: 2024
Type: article
Study design: Case Report
Abstract: BACKGROUND: Colitis has been reported with some anti-CD20 therapies in multiple sclerosis (MS), but not previously with ofatumumab. OBJECTIVES: To report the first case of ofatumumab-associated colitis in MS and discuss its implications. METHODS: Case report. RESULTS: A 56-year-old female with relapsing-remitting multiple sclerosis (RRMS) developed severe colitis 3 months after initiating ofatumumab, requiring hospitalization and treatment discontinuation. CONCLUSION: This case suggests a potential class effect of anti-CD20 therapies, including ofatumumab, in relation to colitis in MS. Clinicians should monitor for gastrointestinal symptoms in MS patients receiving any anti-CD20 therapy.
Source: Multiple Sclerosis Journal
Authors: Ashish D Patel, Alexa Connors, Megan E Esch
Institution: Geisinger Health System
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405127595